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Abstract
© 2018 Human Stem Cell Institute. All  rights reserved. To find effective ways to stimulate
chronic skin wounds healing (including deep burns, diabetic and trophic ulcers) is an actual
multidisciplinary  task.  The  aim  of  our  study  was  to  assess  the  potential  of  using
autodermoplasty in combination with plasmid drug pCMV-VEGFA to optimize skin defects repair
in the experiment. Autodermoplasty was performed on Wistar rats. The size of the skin flap was
22 cm. Immediately after surgery the animals of the test group (n=8) underwent intradermal
injection in the periphery of autotransplant with 1 ml solution containing 0.3 mg of supercoiled
plasmid DNA pCMV-VEGFA, rats of the control group (n=8) received 1 ml of 0.9 % NaCl. The
results  were analyzed in 3,  6,  9 12,  18 days using macroscopic evaluation,  laser  Doppler
flowmetry, histological methods. Macroscopically in the test group necrosis of the transplanted
skin  flap  was  found  at  later  periods  of  observation,  in  one  case  complete  survival  of
autotransplant was observed. The results of laser Doppler flowmetry in the group with plasmid
DNA did not have statistically significant differences with control. The wound defect diameter in
the test group at 12 days was 5,52± 4.80 mm, in the control 12,45±0,82 mm (p=0,03); 2,53±of
2,94 mm and 4,23±3,5 mm (p=0,067) at 18 days, respectively. At 18 days, the average number
of vessels under the flap in the central zone were: of 26±2,9 in the test group and 20±8 in
control; it  the peripheral zone 27±3,4 and of 12,1±3,9 (p=0,035), respectively; in the skin
muscle 21,2±of 3,9 and 12,4±3,6 (p=0,04), respectively. Thus, the use of plasmid drug pCMV-
VEGFA improved the skin healing after autodermoplasty.
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